The Efficacy of Psilocybin in the Treatment of Depression andAnxiety: A Meta-Analysis
Andrew Hodge, Suporn Sukpraprut‐braaten, Robert Strayhan
Current Psychiatry Research and Reviews May 16, 2022 DOI: 10.2174/2666082218666220513142002 via OpenAlex
Summary
AI-generated from the abstractA meta-analysis of clinical trials found that psilocybin significantly reduces symptoms of depression and anxiety compared to control conditions, with low to moderate heterogeneity across studies and no detected publication bias. The effect was observed in short, medium, and long-term time frames. However, the evidence remains preliminary; larger and longer trials are needed before psilocybin could be approved for community use.
Study at a glance
| Characteristics | Meta-analysis Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Topics | Anxiety Psilocybin |
| Keywords | Meta-analysis Mood Clinical psychology |
| Citations | 4 |
| Key finding | Psilocybin significantly reduces depression and anxiety symptoms compared to controls across multiple time frames, with low to moderate heterogeneity and no publication bias. |
Abstract
Background: The use of psychedelic compounds to treat psychiatric disorders has become a very significant topic of research over the past several years. Psilocybin has risen to prominence as one of the most studied among these psychedelic compounds. Multiple trials have already shown that it can be a safe and efficacious treatment for various medical conditions. This study intends to perform a meta-analysis of data reported in clinical trials studying psilocybin’s effect on depression and anxiety. Methods: Articles were searched, screened, and ultimately selected using predetermined inclusion criteria. Data was collected from commonly used psychometric tests that measured mood and anxiety symptoms. Effect sizes were calculated by comparing scores in these tests at baseline and control to experimental groups. Sub-group analysis was performed to assess psilocybin’s effect on depression and anxiety during short, medium, and long-term time frames. Results: Statistical significance was achieved in reducing depression and anxiety symptoms compared to controls in multiple subgroups. Heterogeneity of the effect sizes was calculated using an I2 value which showed low to moderate values. Multiple tools were used to assess publication bias, and none could be found. Conclusion: Although research on psilocybin continues to show promise, the evidence is still at a preliminary phase, and more trials need to be conducted with larger patient populations over longer periods for psilocybin to potentially be approved in a community setting.